Interpace Biosciences (IDXG) posts prelim 2025 revenue and converts Series C preferred

Rhea-AI Filing Summary

Interpace Biosciences, Inc. filed a current report describing preliminary, unaudited revenue for the year ended December 31, 2025, as outlined in a related press release.

The company also reported that all outstanding shares of its Series C Preferred Stock were converted into shares of its common stock, simplifying its equity structure. The press release dated January 20, 2026 is furnished as an exhibit to the report and is not treated as filed for purposes of liability under the Exchange Act.

false 0001054102 0001054102 2026-01-20 2026-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 20, 2026

INTERPACE BIOSCIENCES, INC.

(Exact name of Registrant as specified in its charter)

Delaware		000-24249		22-2919486
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Waterview Plaza, Suite 310, 2001 Route 46

Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

(855) 776-6419

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 20, 2026, Interpace Biosciences, Inc. (the “Company”) issued a press release (the “Press Release”) announcing preliminary and unaudited revenue for the year ended December 31, 2025, along with certain other information including the conversion of preferred stock described below. The full text of the Press Release is furnished as Exhibit 99.1 attached hereto.

Item 7.01 Regulation FD Disclosure.

In the Press Release, the Company also announced that all of the outstanding shares of its Series C Preferred Stock were converted into shares of its common stock.

The information in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 20, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INTERPACE BIOSCIENCES, INC.
	By:	/s/ Thomas W. Burnell
	Name:	Thomas W. Burnell
	Title:	President and Chief Executive Officer

Date: January 20, 2026

FAQ

What did Interpace Biosciences (IDXG) disclose in this 8-K?

Interpace Biosciences disclosed preliminary, unaudited revenue for the year ended December 31, 2025 and announced that all outstanding shares of its Series C Preferred Stock were converted into common stock, as described in a furnished press release.

Which period does Interpace Biosciences' preliminary revenue cover?

The preliminary, unaudited revenue Interpace Biosciences reported relates to the year ended December 31, 2025, as referenced in the press release furnished with the filing.

What change did Interpace Biosciences (IDXG) make to its preferred stock?

The company announced that all outstanding shares of its Series C Preferred Stock were converted into shares of its common stock, as noted under the Regulation FD Disclosure section.

How was the information about Interpace Biosciences' 2025 revenue and stock conversion provided?

The information was provided through a press release dated January 20, 2026, which is furnished as Exhibit 99.1 to the report and referenced in Items 2.02 and 7.01.

Is the Interpace Biosciences (IDXG) press release considered filed with the SEC?

No. The report states that the information in Items 2.02 and 7.01, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.

What exhibits are included with this Interpace Biosciences 8-K?

The exhibits include the press release dated January 20, 2026 as Exhibit 99.1 and the Cover Page Interactive Data File as Exhibit 104.